Human Health Announces FY2025 Interim Results

Demonstrates Steady Growth in Core Business, Advances Digital Transformation and Market Expansion

 

(Hong Kong —— February 26, 2025) Human Health Holdings Limited (“Human Health” or the “Company”, together with its subsidiaries, the “Group”; stock code: 1419), a leading private integrated healthcare service provider in Hong Kong, announces  its consolidated interim results for the six months ended 31 December 2024 (the “Interim Period of FY2025”).

 

During the interim period of FY2025, the Group demonstrated strong resilience and adaptability, further consolidating its leading position in Hong Kong's healthcare sector. Despite facing challenges, the Group achieved notable developments in its core business segments by enhancing operational efficiency, network expansion, and ongoing digital transformation, resulting in robust financial performance.

 

Financial Performance

•   Revenue Growth: The Group's revenue for the interim period of FY2025 was approximately HK$315.8 million, representing an increase of approximately HK$20.6 million or 7.0% as compared with the six months ended 31 December 2023 (the “Interim Period of FY2024”). This growth was mainly driven by the increased revenue from general practice services and specialties services.

 

•   Net Profit Growth: The profit attributable to owners of the Company for the Interim Period of FY2025 was approximately HK$16.8 million.  After the exclusion of the fair value changes of financial assets at fair value through profit or loss and the fair value changes of investment properties, the profit attributable to owners of the Company was approximately HK$22.0 million, representing an increase of approximately HK$2.9 million or 15.0% as compared with that for the Interim Period of FY2024.

 

Business Segment Performance

1. General Practice Segment

•   Revenue reached HK$ 206.6 million, recorded a year- on- year growth of approximately 3.9%.

•   The Group expanded its service network with the launch of a new medical centre in Tsuen Wan and the relocation and expansion of its medical centre in North Point.
•   Through enhancements in service quality, expansion of its customer base, and improved ability to seize market opportunities, the Group has further solidified its position as a leading integrated medical services provider.

 

2. Specialties Segment

•   Revenue reached HK$ 81.3 million, recorded a year- on- year growth of approximately 24.7%.

• Strong performance owning to the expansion of the specilalties services particularly focusing on enhancing the Ophthalmology, Orthopedics, Psychiatry and Paediatric surgery services.
• The introduction of the POLYEYE eye care centre, alongside the engagement of additional ophthalmologists, further solidified the Group’s position as a comprehensive and specialised eye care services provider.

 

3. Dental Segment

•   Revenue reached HK$ 27.9 million, recorded a year- on- year decline of approximately 10.2%, mainly due to the challenges from the convergence within the Greater Bay Area.

• The Group remained optimistic about the future of the dental industry in Hong Kong, as part of its strategic growth initiatives, the Group has announced the acquisition of Monarch Dental Clinic Limited (previously known as Monarch Medical Services Limited) on 3 January 2025, a strategic move aimed at strengthening its market presence and expanding the range of dental services.

 

Development of Healthy Square H2

Healthy Square H2, situated at Star House in Tsim Sha Tsui maintained its position as a premier destination for healthcare solutions by providing personalised and customer-centered services, hosting regular health lectures and workshops aimed at emphasising the importance of well-being and enhancing public awareness of health-related matters.

 

Sustainability and Resilience in the PRC Market

The Group’s business activities in the PRC are primarily operated through the Shanghai Human Health Integrated Medical Centre, managed by Pingan Yingjian Medical Management (Shanghai) Limited, an associate of the Group. The Group remains dedicated to delivering high-quality medical aesthetic services to its clients in mainland China. Despite the prevailing economic challenges and shifting consumer trends in the PRC market, the demand for medical aesthetic services exhibited resilience and growth potential during the Interim Period of FY2025.

 

Mr. Chan Kin Ping, BBS, JP said “The Interim Period of FY2025 marked a significant phase for the Group in the post-pandemic era. Amid a market environment filled with uncertainties, the Group has demonstrated resilience and adaptability by achieving substantial progress in enhancing its operational efficiency, expanding market share, and improving service quality. The Group experienced notable developments in its core business segments. Looking ahead, the Group will actively explore avenues for strategic growth and revenue diversification, focusing on optimizing cost management, streamline processes, and leverage data-driven strategies to optimise efficiencies. At the same time, we will maintain close collaboration with the Hong Kong Government and other institutions to unlock new market opportunities and deliver sustainable value to stakeholders."

 

Business Outlook

The Group continues to embrace a cautiously optimistic stance towards the second

half of FY2025 and will continue to capture growth opportunities through, innovative partnerships and insightful market analysis. The Group will also continue to collaborate with the Hong Kong Government on initiatives such as the Seasonal Influenza Vaccination Subsidy Program (IVSS), the Chronic Disease Co-Care Pilot Program (CDCC), the Colorectal Cancer Screening Program (CRC), and Pilot Rehabilitation Programme for Employees Injured at Work, further enhancing the accessibility and quality of community healthcare services.

 

During the Interim Period of FY2025, the Group significantly increased its digital investments, upgrading IT infrastructure to accelerate digital transformation. It launched its self-developed integrated clinical platform at its general practices medical centres and extended to specialties medical centres, enhancing both patient care standards and operational efficiency. Additionally, the Group introduced an omnichannel messaging platform (such as WhatsApp enquiry function) to expedite responses to public inquiries, enhancing customer engagement and delivering a seamless and personalised experience. Moving forward, the Group will continue to strengthen its digital capabilities by exploring advanced technologies in data management, telemedicine services, and customer engagement tools to elevate healthcare delivery. Committed to its mission, the Group is dedicated to providing comprehensive, highly-coordinated, and person-centered care services to the Hong Kong population while promoting the health and wellness of the community.

 

- END -

 

About Human Health Holdings Limited

Human Health, listed on the Main Board of the Hong Kong Stock Exchange (Stock Code: 1419), is one of the largest medical groups in Hong Kong. Having been serving the community since 1997, the Group operates more than 60 medical centres, with more than 800 professional team members and staff. With an aim to ”Elevate Your Health Values, Elevate Your Life", Human Health provides comprehensive medical services network including general practice, specialties, dental, eye care, physiotherapy, diagnostics & imaging, day procedure and endoscopy, medical aesthetics, Chinese medicine, outreach, rehabilitation and case management, wellness and retail services to provide professional and person-centered care medical and wellness services in Hong Kong.

 

Media Enquiries:

China Times Corporate Advisory Limited

Destiny Cheng

Tel: (852) 6220 0861

Email: pr@ctimes.hk

Fax: (852) 3428 3012